Table 5 Overall and post-relapse EFS in ALL patients by DP peptide pocket 1 and 4 residue

From: HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial

Pocket 1 residue

Overall EFS

Post-relapse EFS

 

No. of events/no. of patients

% (se) at 5 years

% (se) at 10 years

P-value (log-rank test)

No. of events/no. of patients

% (se) at 5 years

% (se) at 10 years

P-value (log-rank test)

Asp84/Asp84

33/80

61.3 (5.4)

58.6 (5.5)

 

18/29

37.6 (9.1)

37.6 (9.1)

 

Asp84/Xa

119/286

61.2 (2.9)

58.3 (2.9)

 

69/113

40.7 (4.6)

38.8 (4.6)

 

X/X

157/432

67.6 (2.3)

64.3 (2.3)

0.09

79/152

51.6 (4.1)

46.0 (4.3)

0.09

Lys69/Lys69

201/500

63.8 (2.1)

60.1 (2.2)

 

109/191

44.7 (3.6)

41.5 (3.7)

 

Lys69/Yb

93/249

65.0 (3.0)

63.0 (3.1)

 

48/88

49.8 (5.3)

44.4 (5.4)

 

Y/Y

15/49

71.4 (6.5)

69.3 (6.6)

0.2

9/15

40.0 (12.6)

40.0 (12.6)

0.7

  1. Abbreviations: ALL, acute lymphoblastic leukemia; Asp, aspartic acid; EFS, event-free survival; Lys, lysine.
  2. aX is either glycine or valine 84 (pocket 1)
  3. bY is either glutamic acid or arginine 69 (pocket 4).
Back to article page